Neskatoties uz sare\u017e\u0123\u012btajiem tirgus apst\u0101k\u013ciem, 2023.\u00a0gada \u201eNoramedas\u201d rezult\u0101ti bija pier\u0101d\u012bjums t\u0101s iztur\u012bbai. Uz\u0146\u0113mumam izdev\u0101s ne vien saglab\u0101t par 7\u00a0% liel\u0101kus ien\u0101kumus, sal\u012bdzinot ar 2022.\u00a0gadu (28,3\u00a0milj., sal\u012bdzinot ar 26,3\u00a0milj.), bet ar\u012b iev\u0113rojami\u00a0\u2013 par 130\u00a0%\u00a0\u2013 izaudz\u0113t pe\u013c\u0146u.<\/p>\n
\u201eB\u016bdami re\u0101listi, ien\u0101kumu pieaugumu nepl\u0101noj\u0101m, tiec\u0101mies saglab\u0101t p\u0101rdo\u0161anu t\u0101d\u0101 pa\u0161\u0101 l\u012bmen\u012b k\u0101 2022.\u00a0gad\u0101, t\u0101d\u0113\u013c gads bija lab\u0101ks, nek\u0101 m\u0113s cer\u0113j\u0101m. Rezult\u0101tus visvair\u0101k noteica profesion\u0101las komandas, ar ko vienm\u0113r ir pat\u012bkami lepoties, p\u016bles,\u201d saka Audrjus \u013beiva [Audrius Leiva<\/em>], \u201eNoramedas\u201d direktors.<\/p>\n Apl\u016bkojot rezult\u0101tus pa valst\u012bm, Latvij\u0101 un Igaunij\u0101 \u201eNoramedas\u201d ien\u0101kumi auga strauj\u0101k (attiec\u012bgi par 19\u00a0% un 9\u00a0%) un ienes\u012bgums bija liel\u0101ks nek\u0101 Lietuv\u0101.<\/p>\n P\u0113c A.\u00a0\u013beivas teikt\u0101, konkurence un z\u0101\u013cu cenu regul\u0113\u0161ana Lietuv\u0101 noteica zem\u0101kas cenas. Atsevi\u0161\u0137os gad\u012bjumos \u201eNorameda\u201d pat bija spiesta p\u0101rtraukt noteiktu z\u0101\u013cu pieg\u0101di, jo tas vairs nebija saimnieciski izdev\u012bgi.<\/p>\n Neskatoties uz ieie\u0161anas tirg\u016b f\u0101zi, \u201eNoramedas\u201d fili\u0101lei Polij\u0101 2024.\u00a0gad\u0101 vajadz\u0113tu augt. Cerams, ka p\u0113c tam, kad komanda b\u016bs papla\u0161in\u0101jusi produktu sortimentu un kompens\u0113jamo z\u0101\u013cu sarakst\u0101 b\u016bs iek\u013cauts jauns medikaments no retas neirolo\u0123isk\u0101s slim\u012bbas, tas atsauksies uz uz\u0146\u0113m\u0113jdarb\u012bbas rezult\u0101tiem.<\/p>\n \u201eTas pal\u012bdz\u0113s mums nostiprin\u0101t poz\u012bcijas Polij\u0101,\u201d ar p\u0101rliec\u012bbu saka \u201eNoramedas\u201d direktors.<\/p>\n Tom\u0113r, run\u0101jot par 2024.\u00a0gadu, A.\u00a0\u013beiva paliek konservat\u012bvs. Iemesli tie pa\u0161i: intens\u012bva konkurence, kr\u012bto\u0161as z\u0101\u013cu cenas, ilga kompens\u0113jamo z\u0101\u013cu gaid\u012b\u0161ana Baltijas farm\u0101cijas tirg\u016b.<\/p>\n Kaut gan Baltijas valstis katru gadu izdod vair\u0101k z\u0101\u013cu kompens\u0101cijai, z\u0101\u013cu pieejam\u012bbai v\u0113l ir j\u0101pan\u0101k Rietumeiropas valstis.<\/p>\n \u201eNoramedas\u201d vad\u012bt\u0101js saka: \u201eFarm\u0101cijas tirgus tiek stipri regul\u0113ts. Nemit\u012bgi rodas izaicin\u0101jumi: stingras kvalit\u0101tes pras\u012bbas attiec\u012bb\u0101 uz glab\u0101\u0161anu noliktav\u0101s un transport\u0113\u0161anu, z\u0101\u013cu pieg\u0101de iepakojumos ar valsts valodu, z\u0101\u013cu nev\u0113lamo blak\u0146u monitorings u.\u00a0c. Taj\u0101 pa\u0161\u0101 laik\u0101 cenas tiek regul\u0113tas un t\u0101m b\u016btu j\u0101b\u016bt vien\u0101m no viszem\u0101kaj\u0101m Eirop\u0101. Mums j\u0101veic past\u0101v\u012bgs monitorings, j\u0101maina sortiments, j\u0101b\u016bt elast\u012bgiem un efekt\u012bviem.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":" Neskatoties uz sare\u017e\u0123\u012btajiem tirgus apst\u0101k\u013ciem, 2023.\u00a0gada \u201eNoramedas\u201d rezult\u0101ti bija pier\u0101d\u012bjums t\u0101s iztur\u012bbai. Uz\u0146\u0113mumam izdev\u0101s ne vien saglab\u0101t par 7\u00a0% liel\u0101kus ien\u0101kumus, sal\u012bdzinot ar 2022.\u00a0gadu (28,3\u00a0milj., sal\u012bdzinot ar 26,3\u00a0milj.), bet ar\u012b iev\u0113rojami\u00a0\u2013 par 130\u00a0%\u00a0\u2013 izaudz\u0113t pe\u013c\u0146u. \u201eB\u016bdami re\u0101listi, ien\u0101kumu pieaugumu nepl\u0101noj\u0101m, tiec\u0101mies saglab\u0101t p\u0101rdo\u0161anu t\u0101d\u0101 pa\u0161\u0101 l\u012bmen\u012b k\u0101 2022.\u00a0gad\u0101, t\u0101d\u0113\u013c gads bija lab\u0101ks, nek\u0101 m\u0113s cer\u0113j\u0101m. […]<\/p>\n","protected":false},"author":220,"featured_media":7402,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_links_to":"","_links_to_target":""},"categories":[141],"tags":[],"_links":{"self":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts\/8544"}],"collection":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/users\/220"}],"replies":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/comments?post=8544"}],"version-history":[{"count":0,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts\/8544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/media\/7402"}],"wp:attachment":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/media?parent=8544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/categories?post=8544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/tags?post=8544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}